1-(3-Cyan-phenyl)-2-nitro-prop-1-en | 15804-73-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-Cyan-phenyl)-2-nitro-prop-1-en
• 英文别名: 3-Cyan-1β-nitropropenyl-benzol；3-Cyan-1-(2-nitro-propenyl)-benzol；3-(2-Nitroprop-1-en-1-yl)benzonitrile；3-(2-nitroprop-1-enyl)benzonitrile
• CAS: 15804-73-6
• 化学式: C₁₀H₈N₂O₂
• 分子量: 188.186
• InChiKey: KIJATRMBSCGLFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  69.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-Cyan-phenyl)-2-nitro-prop-1-en 在 水 、 三氯化铁 、 铁粉 作用下， 生成 3-(2-氧代丙基)苯甲腈
  参考文献：
  名称：

  Gardrat, C., Bulletin des Societes Chimiques Belges, 1984, vol. 93, # 10, p. 897 - 902

  摘要：

  DOI：
• 作为产物：
  描述：

  硝基乙烷 、 3-氰基苯甲醛 在 正丁胺 作用下， 以 甲苯 为溶剂， 生成 1-(3-Cyan-phenyl)-2-nitro-prop-1-en
  参考文献：
  名称：

  Gardrat, C., Bulletin des Societes Chimiques Belges, 1984, vol. 93, # 10, p. 897 - 902

  摘要：

  DOI：

文献信息

• Androgen receptor antagonists
  申请人：Furuya Shuichi

  公开号：US20050101657A1

  公开（公告）日：2005-05-12

  The present invention provides an androgen receptor antagonistic agent and a superior prophylactic or therapeutic agent for hormone-sensitive cancer, which contain a compound of the formula: wherein, R 1 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R 2 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R 3 is a hydrogen atom, a hydrocarbon group which may have substituent(s), an acyl group or a heterocyclic group which may have substituent(s), R 4 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, and R 5 is a cyclic group which may have substituent(s); or a salt thereof, or its prodrug.

  本发明提供了一种雄激素受体拮抗剂，以及一种优越的预防或治疗激素敏感性癌症的药物，其含有式中的化合物：其中，R1是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合的基团或通过硫原子结合的基团，R2是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合的基团或通过硫原子结合的基团，R3是氢原子、可能具有取代基的碳氢基团、酰基或可能具有取代基的杂环基团，R4是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合的基团或通过硫原子结合的基团，R5是可能具有取代基的环状基团；或其盐或前药。
• Process for producing beta-nitro-enamines and intermediates thereof
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0672646A1

  公开（公告）日：1995-09-20

  Disclosed is a process for producing a β-nitroenamine compound represented by the formula I: wherein R₁ and R₂ are the same or different and independently indicate a hydrogen atom or a straight-chain or branched C₁-C₁₀ alkyl group which may be optionally substituted with at least one group selected from the group consisting of a halogen atom, a lower alkoxy group, an aryloxy group, hydroxyl group or an aryl group, or an aryl group which may be optionally substituted with at least one group selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group, an aryl group, an aryloxy group, a nitro group, a cyano group, an acylamino group, a lower dialkylamino group, an arylamino group, a hydroxyl group, an arylsulfonyl group, a mercapto group, a lower alkylthio group or an arylthio group, and R₁ and R₂ may bond together to form a cycloalkyl or bicycloalkyl group; and R₃ is a hydrogen atom, a lower alkyl group, a cycloalkyl group or an aralkyl group; and an intermediate for producing the β-nitroenamine compound.

  本发明公开了一种生产由式 I 代表的 β-硝基烯胺化合物的工艺： 其中R₁和R₂相同或不同，且独立地表示氢原子或直链或支链C₁-C₁₀烷基，该烷基可任选被至少一个选自由卤素原子、低级烷氧基、芳氧基、羟基或芳基组成的组中的基团取代，或可任选被至少一个选自由卤素原子、低级烷氧基、芳氧基、芳氧基、羟基或芳基组成的组中的基团取代的芳基、低级烷基、低级烷氧基、芳基、芳氧基、硝基、氰基、酰氨基、低级二烷基氨基、芳氨基、羟基、芳磺酰基、巯基、低级烷硫基或芳硫基，且 R₁ 和 R₂ 可键合在一起形成环烷基或双环烷基；和 R₃ 是氢原子、低级烷基、环烷基或芳烷基；以及生产 β-硝基烯胺化合物的中间体。
• ANDROGEN RECEPTOR ANTAGONISTS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1466902A1

  公开（公告）日：2004-10-13

  The present invention provides an androgen receptor antagonistic agent and a superior prophylactic or therapeutic agent for hormone-sensitive cancer, which contain a compound of the formula: wherein, R1 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom; R2 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R3 is a hydrogen atom, a hydrocarbon group which may have substituent (s) , an acyl group or a heterocyclic group which may have substituent(s), R4 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, and R5 is a cyclic group which may have substituent(s); or a salt thereof, or its prodrug.

  本发明提供了一种雄激素受体拮抗剂和一种激素敏感性癌症的高级预防或治疗剂，其中含有一种式化合物： 其中，R1 是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合的基团或通过硫原子结合的基团；R2 是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合 的基团或通过硫原子结合的基团； R3 是氢原子、烃基，该烃基可能具有取代基（s）、R4 是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合的基团或通过硫原子结合的基团，R5 是可能带有取代基的环状基团；或其盐或其原药。
• US5597940A
  申请人：——

  公开号：US5597940A

  公开（公告）日：1997-01-28
• US5639895A
  申请人：——

  公开号：US5639895A

  公开（公告）日：1997-06-17